Opens in a new tab

Enhancing Quality of Life Through Awareness: Diabetes Awareness and GRP Japan Website

Announcement, Announcement

Announcement

Dear Valued Customers,

Thank you for your continued patronage and support.

From Monday, November 10, 2025, globally and nationally in Japan, there are widespread efforts to promote awareness of diabetes and substantially improve the quality of life (QOL) for those affected.

Global Regulatory Partners (GRP) is proud to support these essential efforts. In Japan, GRP will feature a diabetes awareness image (click HERE to view) on our homepage throughout the month of November, complementing the activities of Diabetes Week and World Diabetes Day on November 14, 2025.

We firmly believe that increasing knowledge about diabetes and effective solutions significantly enhances patient QOL and empowers their support networks.  We encourage you to read our featured article, which details how access to a unique treatment like Baqsimi® (nasal glucagon powder) can dramatically change the patient experience and elevate QOL.

Read the Full Article HERE.
Download this announcement here.

Global Regulatory Partners GK

Related News

  • GLOBAL REGULATORY PARTNERS JAPAN JOINS THE TOKYO CHAMBER OF COMMERCE AND INDUSTRY (TCCI)

    Global Regulatory Partners Japan (GRP Japan) is pleased to announce that it has joined the Tokyo Chamber of Commerce and Industry (TCCI / 東京商工会議所), effective October 2026. GRP Japan will belong to the Minato Branch (港支部), one of TCCI’s 23 ward-based branches, strengthening the company’s connection with the local business community in Minato Ward.
    View More

  • Global Regulatory Partners Announces MHLW Approval of Aflibercept Biosimilar Prefilled Syringe in Japan

    Tokyo, Japan - October 26, 2026 - Global Regulatory Partners GK (GRP) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) granted marketing approval on October 13, 2026 for Aflibercept BS Solution for Intravitreal Injection Kit 40 mg/mL [GRP] (prefilled syringe (PFS) presentation), a biosimilar to EYLEA®¹ (aflibercept), for ophthalmic use.
    View More

  • Baqsimi® Nasal Powder Featured in the September 2026 Issue of Nikkei DI

    Global Regulatory Partners GK (GRP Japan) is pleased to share that Baqsimi® Nasal Powder, for which GRP Japan serves as the Marketing Authorization Holder (MAH) in Japan, is featured in the September 2026 issue of Nikkei Drug Information (Nikkei DI). Nikkei DI is a professional publication for pharmacists and other healthcare professionals in Japan, providing information on pharmaceuticals, clinical practice, medication management and developments relevant to pharmacy practice.
    View More

  • GRP JAPAN JOINS THE JAPAN RADIOPHARMACEUTICALS ASSOCIATION

    Tokyo, Japan — October 2026 — Global Regulatory Partners Japan (GRP Japan) is pleased to announce that it has joined the Japan Radiopharmaceuticals Association, effective October 2026. The membership marks an important step in GRP Japan’s continued expansion into the radiopharmaceutical and nuclear medicine sector, complementing the company’s established capabilities in pharmaceuticals, biologics, medical devices, and diagnostics. As a Marketing Authorization Holder (MAH) and local regulatory partner for international healthcare companies entering Japan, GRP Japan is expanding its capabilities to support the specialized regulatory, quality, importation, supply-chain, and lifecycle requirements associated with radiopharmaceutical products. Through its membership, GRP Japan looks forward to industry collaboration and to contributing its regulatory and market-access experience to the continued development of the sector in Japan.
    View More